NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis $1.26 -0.01 (-0.39%) As of 10:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sunshine Biopharma Stock (NASDAQ:SBFM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sunshine Biopharma alerts:Sign Up Key Stats Today's Range$1.26▼$1.3150-Day Range$1.22▼$2.3952-Week Range$1.17▼$23.20Volume27,437 shsAverage Volume602,504 shsMarket Capitalization$3.42 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewSunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.Read More… Sunshine Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreSBFM MarketRank™: Sunshine Biopharma scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSunshine Biopharma has received no research coverage in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sunshine Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.78% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 13.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.78% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 13.66%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentSunshine Biopharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sunshine Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Sunshine Biopharma is held by insiders.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBFM Stock News HeadlinesSunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6 at 4:57 PM | finanznachrichten.deSunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.May 8, 2025 | Priority Gold (Ad)This Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deSee More Headlines SBFM Stock Analysis - Frequently Asked Questions How have SBFM shares performed this year? Sunshine Biopharma's stock was trading at $3.00 at the beginning of the year. Since then, SBFM stock has decreased by 57.8% and is now trading at $1.2650. View the best growth stocks for 2025 here. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of $9.00 by $9.94. The company had revenue of $8.44 million for the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 17.89% and a negative net margin of 12.82%. When did Sunshine Biopharma's stock split? Shares of Sunshine Biopharma reverse split on the morning of Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sunshine Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/05/2024Today5/08/2025Next Earnings (Estimated)5/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SBFM CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+1,085.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($150.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,510,000.00 Net Margins-12.82% Pretax Margin-12.48% Return on Equity-17.89% Return on Assets-14.25% Debt Debt-to-Equity RatioN/A Current Ratio5.74 Quick Ratio3.57 Sales & Book Value Annual Sales$34.87 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1,651.69 per share Price / Book0.00Miscellaneous Outstanding Shares2,707,000Free Float1,223,000Market Cap$3.42 million OptionableNot Optionable Beta1.35 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SBFM) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.